This week, the Trump administration reversed its position on reforming the drug rebate system. Analysts and advocates say there may be better approaches to lower out-of-pocket costs.
By Laura Santhanam
Amid the ongoing opioid epidemic, drug manufacturers, doctors and pharmacists have all come under fire. But it's a drug distributor, a company called RDC, at the center of a new federal criminal case that equates its business operations with illegal…
The hearing marks the first time lawmakers have called top industry executives to account for rising prices that are squeezing Americans.
By Ricardo Alonso-Zaldivar, Matthew Perrone, Associated Press
House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum.
By Ricardo Alonso-Zaldivar, Associated Press
By Megan Thompson, Mori Rothman
Americans pay more for prescription drugs than any country in the world, and the pharmaceutical industry earns billions in profits each year. Critics blame pharmacy benefit managers, or PBMs, for a portion of those high costs through their role as…
By Lev Facher, STAT
Federal agencies on Thursday announced charges in what Attorney General Jeff Sessions called “the largest health care fraud takedown in American history,” an investigation into over $2 billion in alleged fraud by doctors, pharmacists, and nurses.
Rushing to judgment is misguided. There are no quick fixes here, and while the Trump proposals are viewed as fatally flawed by many experts, they also include some worthy ideas.
By Emily Kopp, Kaiser Health News
The cost of insulin medications has steadily risen over the past decade by nearly 300 percent.
By Sheila Kaplan, STAT
More than 1,300 lobbyists roamed the halls of Congress on the 21st Century Cures Act, and disclosure reports show most of them were working for pharmaceutical companies.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.